ArticleAIDS (London, England)2025
Outcomes in people with HIV who resume or switch to bictegravir/emtricitabine/tenofovir alafenamide following a treatment interruption.
Article in AIDS (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Real-World Persistence in Adults with HIV and Mental Health or Substance Use Disorders After Restarting Antiretroviral Therapy in the United States.Advances in therapy · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTreatment adherence remains critical in maintaining HIV RNA suppression on antiretroviral therapy. High genetic barrier regimens constructed with three long half-life agents may prevent resistance emergence and can be potentially started or restarted after antiretroviral treatment interruption.
methodsData from the TRIO US HIV cohort were used to identify adult people with HIV initiating a new ART regimen from January 2021 to November 2023 and describe prevalence of treatment interruptions (defined as ≥90 days without dispensed ART). Virologic outcomes were assessed among those restarting or switching to B/F/TAF after treatment interruption.
resultsOf 2710 people with HIV, 765 (28%) experienced treatment interruption. Compared to individuals without treatment interruptions, those with treatment interruptions had higher proportion of women (24 vs. 19%), Black race (50 vs. 35%), substance use (14 vs. 9%), CD4 + cell count less than 200 cells/mm 3 (15 vs. 8%) and lower proportion with commercial insurance (48 vs. 62%) or virologic suppression at initiation (76 vs. 85%). Among 379 who restarted or switched to B/F/TAF following treatment interruption, 245 (65%) were suppressed at restart; 137 (56%) had at least one viral load after treatment interruption, of whom 129 (94%) maintained suppression. Of 87 with unknown viral status at restart, 46 (53%) had at least one viral load during follow-up, of whom 44 (96%) achieved suppression. Among 47 viremic at restart, 27 (57%) had at least one viral load after treatment interruption. Of them, 70% were suppressed during follow-up. No integrase inhibitor resistance emergence was observed.
conclusionHigh levels of suppression following treatment interruption may suggest B/F/TAF regimen forgiveness making it an appropriate choice for treatment switch or restart.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.